Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Myriad Genetics (MYGN) Misses Q1 EPS by 24c; Lowers Outlook
November 4, 2019 4:16 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.08, $0.24 worse than the analyst estimate of $0.32. Revenue for the quarter came in at $186.3 million versus the consensus estimate of $202.1 million.
"We had a challenging start to fiscal year 2020 as hereditary cancer revenue accrual from small payers was impacted by the... More
